title: A report from the European Society of Cardiology Congress 2011 (August 27-31, 2011 -- Paris, France).
abstract: Paris, known as the city of light or the illuminated city, is, thus, an appropriate site for a major international conference in which advances in research and new findings and observations are reported and discussed, as was the case during this year's European Society of Cardiology meeting. Indeed, not only were new results from major clinical trials presented, but initial clinical and preclinical research results were also reported during the meeting oral and poster sessions which, in many cases, represent major steps towards improved cardiovascular pharmacotherapy for many common diseases shortening the lives of people around the world. For those who could not attend the meeting, Drugs of Today has wrapped up the major take-home messages from the meeting in the following report.
authors.affiliation: Thomson Reuters, Barcelona, Spain. xavier.rabasseda@thomsonreuters.com
authors.forename: X
authors.initials: X
authors.lastname: Rabasseda
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000150:complications; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000209:etiology; D050171:Dyslipidemias / Q000150:complications; D005602:France; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D012307:Risk Factors